S-1/A: Invizyne Technologies Files Amendment for $15 Million IPO with Investor Rights Offering

Invizyne Technologies Inc. files an amendment to its Form S-1 registration statement for a $15 million initial public offering, including a unique investor rights offering.

Summary

• Invizyne Technologies Inc. has filed Amendment No. 5 to its Form S-1 registration statement with the SEC.
• The company is planning an initial public offering (IPO) of 3,750,000 shares of common stock at a price of $4.00 per share, aiming to raise $15 million.
• The offering includes a non-transferable contractual right for investors to receive up to one additional share of common stock for each share purchased, contingent on certain conditions.
• MDB Capital Holdings, LLC, the majority holder of Invizyne's common stock, is offering 8,027,538 shares in the IPO.
• The company intends to list its common stock on The Nasdaq Capital Market under the symbol IZTC.
• Invizyne is an emerging growth company and has taken advantage of certain reduced disclosure obligations.
• The company plans to use the net proceeds from the offering to expand production capabilities, increase staff, expand business development, sales and marketing efforts, expand research and development, and add to working capital.
• The underwriter has a 45-day option to purchase up to 562,500 additional shares to cover over-allotments.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While it highlights the potential of Invizyne's technology and its market opportunities, it also acknowledges the company's pre-revenue stage, dependence on future funding, and various risks associated with its business and the IPO. The inclusion of a going concern statement from the independent accountants further tempers the sentiment.

Positives

• The company is developing a biomanufacturing platform, SimplePath, which it believes will be an important alternative to current methods of chemical compound production.
• The company has received US government grants, particularly from the Department of Energy (DOE) and the National Institutes of Health (NIH), for work related to isobutanol and cannabinoids.
• The company's commercialization strategy is to collaborate with third parties to engage in aspects of product research, testing, marketing, manufacturing, and product distribution.
• The company is an emerging growth company and has taken advantage of certain reduced disclosure obligations.

Negatives

• Invizyne is a pre-revenue, development stage company with a limited operating history.
• The company anticipates needing additional funding in the future to continue developing its business plan.
• The independent accountants to the Company have issued their report with a going concern statement.
• The synthetic biological platform being developed by the Company may not be able to develop a pipeline of commercial products.
• The company does not have any sales, marketing, manufacturing and distribution capabilities or arrangements, and will need to create these as it moves towards commercialization of its products.

Risks

• The company may not be able to sustain its operations or become profitable in the future.
• The company may not be able to develop a pipeline of commercial products.
• The company may face regulatory hurdles before its bio-synthesized compounds can be marketed and commercially used.
• The company is highly dependent on retaining its scientific staff and being able to hire additional scientific and related managerial staff.
• Conditions in the laboratory setting may not be reproduced in a commercial setting.
• The company's processes rely on the need for purified enzymes and co-factors, which are energy molecules.
• The company is highly dependent on a small number of products, which are based on its principal technology.
• The company may face extensive competition from legacy processes and other companies seeking to use bio-manufacturing and enzyme pathways to develop products alternative to traditional chemicals and petroleum based products.
• The company may be unable to protect the intellectual property used in its technology platform and products.
• The company may fail to comply with its obligations in the agreements under which it licenses development or commercialization rights to products or technology from third-parties.
• The company will incur increased costs as a result of operating as a public company.
• The company is an emerging growth company under the JOBS Act and it cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make its Common Stock less attractive to investors.
• The company is a smaller reporting company within the meaning of the Securities Act of 1933, as amended, or the Securities Act, and if it takes advantage of certain exemptions from disclosure requirements available to smaller reporting companies, this could make its securities less attractive to investors and may make it more difficult to compare its performance with other public companies.
• Certain recent initial public offerings of companies with relatively small public floats have experienced extreme volatility that was seemingly unrelated to the underlying performance of the company.
• Concentration of ownership among the company's existing executive officers, directors and significant stockholders may prevent new investors from influencing significant corporate decisions.
• The price of the company's Common Stock may have little or no relationship to the historical sales price of its capital stock in its private placement transactions to date.
• The company's failure to meet the continued listing requirements of Nasdaq could result in a delisting of its Common Stock.
• The company may allocate the net proceeds from this offering in ways that differ from the estimates discussed in the section titled Use of Proceeds and with which you may not agree, and if the company does not use those proceeds effectively your investment could be harmed.
• You will experience immediate dilution in the book value per share of the Common Stock you purchase.
• Because the underwriter, MDB Capital, is a wholly owned subsidiary of MDB, and MDB prior to the offering beneficially owns 62.86% of the company's Common Stock, there may be a conflict of interest among the Company, underwriter and MDB in conducting the offering and its terms.
• Holders of Common Stock who purchase shares in this offering, but who do not register and continuously hold those shares in their name for two years will lose the Long Term Investor Right and the opportunity to receive additional shares from the company if those Long Term Investor Rights are triggered.
• Registering and keeping the shares of Common Stock purchased in this offering in the shareholders name can delay your ability to dispose of the shares and could cause partial or full loss of your investment in the event of a rapid decline in the company's share price.
• If the Long Term Investor Right is triggered the company will deliver additional shares according to a formula limited to no more than one share for each share acquired in this offering which may still lead to partial or substantial loss of your investment and further dilution to the holders of the company's Common Stock.

Future Outlook

The company intends to continue to make investments in its business to respond to business opportunities and challenges, including refining its technologies, developing new products, enhancing its operating infrastructure, and expanding its operations.

Management Comments

• Invizyne believes it has discovered and is developing a process that could significantly change biomanufacturing.
• Management believes that Invizynes technology is a differentiated and unique synthetic biology platform.
• Management believes the platform will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than the typical methods used today.

Industry Context

The document highlights the growing biobased industry and the increasing focus on developing bio-derived replacements for basic chemicals. It positions Invizyne's SimplePath platform as a potential disruptor in the biomanufacturing space, offering advantages over traditional chemical synthesis, natural extraction, and synthetic biology.

Comparison to Industry Standards

• The document mentions companies like Debut Biotech and Solugen Inc. that also promote cell-free enzymatic systems, but their processes appear to use simple one to two step pathways.
• Codexis, Inc. partnered with Tate & Lyle and Merck & Co., Inc. on different, highly specific projects that use multi enzyme pathways, such as enzymatic Islatravir synthesis, illustrating the potential for complex enzyme cascades, but their principal mission diverges from the enzymatic manufacturing of more general chemicals.
• The document also mentions companies that focus on enzyme engineering, such as Codexis, Inc., Allozymes Pte Ltd., Enzymit Ltd., Zymtronix Catalytic Systems, Inc., Arzeda Corp. and Quantumzyme LLP.
• In the biofuels space, the document mentions companies such as Valero Energy Corporation, ADM Corporation, Cargill Company, Gevo, Inc. and Butamax Advanced Biofuels LLC that focus on ethanol technologies.

Related Party Transactions

• As of June 30, 2024, MDB Capital Holdings, LLC has advanced and loaned an aggregate of $3,189,359 to the Company.
• The advances consists of amounts paid on behalf of the Company related to audit fees, executive services and other recurring chargebacks.
• The related party loans are undocumented and amount to $2,871,498 as of June 30, 2024, and bear interest at a rate of 5%, compounding annually.
• The Company intends to repay the full amount of the intercompany payables and all outstanding interest due in the aggregate amount of $31,498 as of June 30, 2024, promptly after the consummation of this offering.

Stakeholder Impact

• Shareholders will experience immediate dilution in the book value per share of the Common Stock they purchase.
• The success of the company depends on its ability to attract and retain qualified personnel.
• The company's ability to obtain adequate financing or financing on terms satisfactory to it, when it requires it, could significantly limit its ability to continue supporting its business growth and responding to business opportunities and challenges.

Next Steps

• The company intends to list its common stock on The Nasdaq Capital Market under the symbol IZTC.
• The company plans to use the net proceeds from the offering to expand production capabilities, increase staff, expand business development, sales and marketing efforts, expand research and development, and add to working capital.

Key Dates

Keywords

IPO, initial public offering, biomanufacturing, SimplePath, cannabinoids, isobutanol, emerging growth company, MDB Capital, biotechnology, enzymes